On September 2, Teva Pharmaceutical rose 5.11% in pre-market trading, trading at $37.99/share, with turnover of approximately $4.49 million. The rally was directly catalyzed by the company's announcement of positive topline results from an ongoing Phase 2a clinical trial of its investigational anti-IL-15 antibody TEV-408 in adults with celiac disease.

According to the company, a single subcutaneous dose of TEV-408 demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. The drug was well tolerated with no emerging safety signals, and additional analyses are underway, with further data expected at a future scientific meeting. This breakthrough adds to a series of recent pipeline milestones, including the FDA's acceptance of a new drug application for ecopipam in pediatric Tourette syndrome with a target action date in late Q1 of next year, a planned Phase 2b study of TEV-408 in vitiligo, and the acquisition of BioXcel Therapeutics' Igalmi assets for up to $125 million. These developments collectively reinforce market confidence in Teva's innovation-driven transformation strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)